US Stock Market Intraday Update: RTSN Surges 20.11% to Hit ATH; Why Is Capital Rushing In Without Positive Catalysts?

US Stock Market Intraday Update

Retension Pharmaceuticals rose 20.11%, hitting an ATH (All-Time High), with no significant recent news. Trading was active with clear capital flows. Considering sector and industry trends, the stock showed significant volatility, and the specific reasons require further observation.

Top Stocks by Industry Turnover

Moderna rose 3.33%. Based on recent key news:

1. On October 16, Citigroup analysts downgraded Moderna to "Sell" with a target price of $80, pointing out that the company's valuation was too high, putting pressure on its stock price.

2. On October 19, Moderna presented clinical data for mRNA-3927 in the treatment of propionic acidemia at the SSIEM conference, causing the stock price to rise 8.23%, reflecting the market's positive reaction to its R&D progress.

3. On October 9, Moderna was included in the Nasdaq 100 Index, increasing allocation demand from passive institutional investors and driving the stock price up. The revaluation of the mRNA technology platform has attracted high market attention.

Silence Therapeutics rose 125.40%. Based on recent key news:

1. On October 19, Merck KGaA announced the acquisition of Silence Therapeutics for $1.3 billion. This news pushed Silence Therapeutics' pre-market stock price to double to $19.62, and it continued to rise during trading hours, hitting a 52-week high. Source: Reuters

2. On October 19, Merck KGaA stated that it would acquire Silence Therapeutics' American Depositary Shares for $20 per share in cash, representing a 130% premium over the previous Friday's closing price. This move further boosted market confidence in the stock. Source: Reuters

3. On October 19, Silence Therapeutics confirmed that it had reached a final agreement with Merck KGaA, with the transaction expected to be completed in the first quarter of 2027. This news enhanced investors' expectations for the company's future development. Source: MT Newswires M&A activity in the biotechnology industry is frequent, attracting high market attention.

Disc Medicine rose 37.39%. Based on recent key news:

1. On October 19, Disc Medicine announced that its bitopertin achieved success in the APOLLO Phase 3 trial, meeting all primary and secondary endpoints, significantly reducing phototoxic reactions and improving light tolerance. This news drove a sharp increase in the stock price. Source: GlobeNewswire

2. On October 19, Disc Medicine planned to resubmit its NDA application by the end of 2026, with an FDA decision expected by mid-2027. This plan strengthened market confidence in the company's future development. Source: GlobeNewswire

3. On October 18, Wells Fargo analyst Derek Archila maintained a Buy rating on Disc Medicine and set a target price of $86, with analysts consensus indicating strong upside potential for the stock. Source: TipRanks The biopharmaceutical industry has been active recently, with obvious capital inflows.

Top Stocks by Industry Market Capitalization

AbbVie fell 0.60%, with increased trading volume. Based on recent key news:

1. On October 16, AbbVie's Skyrizi new subcutaneous injection formulation released positive clinical data, supporting FDA approval and potentially extending patent protection periods, boosting market confidence.

2. On October 16, capital shifted from tech stocks to large pharmaceutical companies, with AbbVie's stock price approaching an ATH (All-Time High), reflecting investors' search for defensive positioning.

3. On October 15, AbbVie's stock price hit an ATH (All-Time High), with a cumulative monthly gain of 9.78%, demonstrating market confidence in its stable growth. The pharmaceutical sector performed strongly, with obvious capital inflows.